Professional Documents
Culture Documents
Archive
University of Zurich
University Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Wussler, Desiree ; Kozhuharov, Nikola ; Tavares Oliveira, Mucio ; Bossa, Aline ; Sabti, Zaid ; Nowak, Albina ;
Murray, Karsten ; du Fay de Lavallaz, Jeanne ; Badertscher, Patrick ; Twerenbold, Raphael ; Shrestha, Samyut ;
Flores, Dayana ; Nestelberger, Thomas ; Walter, Joan ; Boeddinghaus, Jasper ; Zimmermann, Tobias ; Koechlin,
Luca ; von Eckardstein, Arnold ; Breidthardt, Tobias ; Mueller, Christian
Abstract: BACKGROUND The clinical utility of procalcitonin in the diagnosis and management of pneumonia
remains controversial. METHODS We assessed the clinical utility of procalcitonin in 2 prospective studies: first,
a multicenter diagnostic study in patients presenting to the emergency department with acute dyspnea to directly
compare the diagnostic accuracy of procalcitonin with that of interleukin 6 and C-reactive protein (CRP) in the
diagnosis of pneumonia; second, a randomized management study of procalcitonin guidance in patients with
acute heart failure and suspected pneumonia. Diagnostic accuracy for pneumonia as centrally adjudicated by 2
independent experts was quantified with the area under the ROC curve (AUC). RESULTS Among 690 patients
in the diagnostic study, 178 (25.8%) had an adjudicated final diagnosis of pneumonia. Procalcitonin, interleukin
6, and CRP were significantly higher in patients with pneumonia than in those without. When compared to
procalcitonin (AUC = 0.75; 95% CI, 0.71-0.78), interleukin 6 (AUC = 0.80; 95% CI, 0.77-0.83) and CRP (AUC =
0.82; 95% CI, 0.79-0.85) had significantly higher diagnostic accuracy (P = 0.010 and P < 0.001, respectively). The
management study was stopped early owing to the unexpectedly low AUC of procalcitonin in the diagnostic
study. Among 45 randomized patients, the number of days on antibiotic therapy and the length of hospital stay
were similar (both P = 0.39) in patients randomized to the procalcitonin-guided group (n = 25) and usual-care
group (n = 20). CONCLUSIONS In patients presenting with dyspnea, diagnostic accuracy of procalcitonin for
pneumonia is only moderate and lower than that of interleukin 6 and CRP. The clinical utility of procalcitonin
was lower than expected. SUMMARY Pneumonia has diverse and often unspecific symptoms. As the role of
biomarkers in the diagnosis of pneumonia remains controversial, it is often difficult to distinguish pneumonia
from other illnesses causing shortness of breath. The current study prospectively enrolled unselected patients
presenting with acute dyspnea and directly compared the diagnostic accuracy of procalcitonin, interleukin 6,
and CRP for the diagnosis of pneumonia. In this setting, diagnostic accuracy of procalcitonin for pneumonia
was lower as compared to interleukin 6 and CRP. The clinical utility of procalcitonin was lower than expected.
CLINICALTRIALSGOV IDENTIFIER: NCT01831115.
DOI: https://doi.org/10.1373/clinchem.2019.306787
2
Clinical Chemistry 65:12 Infectious Disease
1532–1542 (2019)
BACKGROUND: The clinical utility of procalcitonin in the procalcitonin-guided group (n ⫽ 25) and usual-care
the diagnosis and management of pneumonia remains group (n ⫽ 20).
controversial.
CONCLUSIONS: In patients presenting with dyspnea, diag-
METHODS: We assessed the clinical utility of procalci- nostic accuracy of procalcitonin for pneumonia is only
tonin in 2 prospective studies: first, a multicenter diag- moderate and lower than that of interleukin 6 and CRP.
nostic study in patients presenting to the emergency de- The clinical utility of procalcitonin was lower than
partment with acute dyspnea to directly compare the expected.
diagnostic accuracy of procalcitonin with that of inter-
leukin 6 and C-reactive protein (CRP) in the diagnosis of SUMMARY: Pneumonia has diverse and often unspecific
pneumonia; second, a randomized management study of symptoms. As the role of biomarkers in the diagnosis of
procalcitonin guidance in patients with acute heart fail- pneumonia remains controversial, it is often difficult to
ure and suspected pneumonia. Diagnostic accuracy for distinguish pneumonia from other illnesses causing
pneumonia as centrally adjudicated by 2 independent shortness of breath. The current study prospectively en-
experts was quantified with the area under the ROC rolled unselected patients presenting with acute dyspnea
curve (AUC). and directly compared the diagnostic accuracy of procal-
citonin, interleukin 6, and CRP for the diagnosis of
RESULTS: Among 690 patients in the diagnostic study,
pneumonia. In this setting, diagnostic accuracy of pro-
178 (25.8%) had an adjudicated final diagnosis of pneu- calcitonin for pneumonia was lower as compared to in-
monia. Procalcitonin, interleukin 6, and CRP were terleukin 6 and CRP. The clinical utility of procalcitonin
significantly higher in patients with pneumonia than in was lower than expected.
those without. When compared to procalcitonin
(AUC ⫽ 0.75; 95% CI, 0.71– 0.78), interleukin 6 CLINICALTRIALS.GOV IDENTIFIER: NCT01831115.
© 2019 American Association for Clinical Chemistry
(AUC ⫽ 0.80; 95% CI, 0.77– 0.83) and CRP (AUC ⫽
0.82; 95% CI, 0.79 – 0.85) had significantly higher diag-
nostic accuracy (P ⫽ 0.010 and P ⬍ 0.001, respectively).
The management study was stopped early owing to the Pneumonia has diverse and often unspecific symptoms
unexpectedly low AUC of procalcitonin in the diagnostic such as cough, fever, or dyspnea. In dyspneic patients,
study. Among 45 randomized patients, the number of acute heart failure (AHF)11 is another common underly-
days on antibiotic therapy and the length of hospital stay ing disorder and frequently occurs in parallel (1, 2 ). Al-
were similar (both P ⫽ 0.39) in patients randomized to though the clinical introduction of natriuretic peptides as
1 †
Cardiovascular Research Institute Basel (CRIB) and Department of Cardiology, University Hos- D. Wussler and N. Kozhuharov contributed equally and should be considered first au-
pital Basel, University of Basel, Switzerland; 2 Department of Internal Medicine, University thors.
Hospital Basel, University of Basel, Switzerland; 3 GREAT network; 4 Emergency Department, Received April 28, 2019; accepted September 10, 2019.
INCOR, Sao Paulo, Brasil; 5 Department of Cardiology, Hospital Linth, Uznach, Switzerland; Previously published online at DOI: 10.1373/clinchem.2019.306787
6
Department of Endocrinology and Clinical Nutrition, University Hospital Zurich, Zurich, Swit- 姝 2019 American Association for Clinical Chemistry
zerland; 7 Division of Internal Medicine, University Psychiatry Clinic Zurich, Zurich, Switzer- 11
Nonstandard abbreviations: AHF, acute heart failure; CAP, community-acquired pneu-
land; 8 Department of Cardiology, University of Illinois, Chicago, IL; 9 Department of Cardiac monia; CRP, C-reactive protein; BASEL V, basics in acute shortness of breath evaluation;
Surgery, University Hospital Basel, University of Basel, Basel, Switzerland; 10 Department of ED, emergency department; BNP, B-type natriuretic peptide; NT-proBNP, N-terminal
Laboratory Medicine, University Hospital Zurich, Zurich, Switzerland. pro-B-type natriuretic peptide; HAP, hospital-acquired pneumonia; HCAP, healthcare-
* Address correspondence to this author at: Department of Cardiology and Cardiovascular associated pneumonia; AUC, area under the curve.
Research Institute Basel (CRIB), University Hospital Basel; Petersgraben 4, CH-4031 Ba-
sel, Switzerland. E-mail christian.mueller@usb.ch.
1532
Procalcitonin in the Diagnosis of Pneumonia
biomarkers has substantially facilitated the early diagno- guidelines for studies of diagnostic accuracy (see Table 1
sis of AHF and their use is consistently recommended in in the online Data Supplement), vouched for the data
both US and European clinical practice guidelines (3–5 ), and analysis, wrote the paper, and decided to publish.
the role of biomarkers in the diagnosis of pneumonia is
more controversial. For these reasons, early diagnosis Adjudication of the final diagnosis. The final diagnosis of
and management of patients with pneumonia is often the illness causing shortness of breath was adjudicated by
challenging. 2 independent cardiologist–internists who had access to
In the absence of a large pivotal diagnostic study all patients’ medical records such as clinical history, phys-
directly comparing the currently available inflammatory ical examination, available laboratory findings, 12-lead
biomarkers, clinical practice guidelines differ in their electrocardiogram, chest x-ray, echocardiography, CT of
recommendations. For instance, for the diagnosis of the chest, microbiological findings, the response to ther-
community-acquired pneumonia (CAP), British practice apy, and autopsy data for patients who died in hospital.
guidelines recommend C-reactive protein (CRP) (6 ), All laboratory findings obtained through the clini-
whereas the American Infectious Diseases Society of cian’s routine diagnostic workup were available for the
America/American Thoracic Society guidelines favor adjudicating physician. These findings were defined as
procalcitonin (7 ). Similar uncertainties relate to the use internal measurements including one of the natriuretic
of procalcitonin in tailoring the duration of antibiotic peptides with class I recommendation [B-type natri-
therapy (8 –12 ). uretic peptide (BNP) or N-terminal pro-B-type natri-
To address these unmet needs, we aimed to perform uretic peptide (NT-proBNP)] (4, 5 ), white blood cell
2 prospective studies to investigate the clinical utility of count, and CRP. Physicians also were able to order
procalcitonin: first, a multicenter diagnostic study per- procalcitonin at their discretion. Adjudicating physi-
formed in patients presenting with acute dyspnea to en- cians were blinded to measurements from study blood
sure broad inclusion criteria enrolling as many pneumo- samples. These measurements were defined as external
nia patients as possible to directly compare the diagnostic results including all interleukin 6 measurements and
accuracy of procalcitonin with that of interleukin 6 and procalcitonin measurements in patients in whom the
CRP; second, a randomized management study of pro- treating physician had not ordered procalcitonin as
calcitonin guidance in patients with pneumonia and con- part of the clinical diagnostic workup. In situations of
comitant AHF (13 ). disagreement about the final diagnosis, cases were re-
viewed and adjudicated in conjunction with a third
Methods cardiologist–internist.
Adjudicated pneumonia as primary end point. In cases of
DIAGNOSTIC STUDY
pneumonia, diagnosed according to criteria from Fine et
al. and Leroy et al. (14, 15 ), all cases of pneumonia were
Study design and study population. Basics in Acute Short- required to have a new infiltrate on chest x-ray or CT of
ness of Breath Evaluation (BASEL V; ClinicalTrials.gov the chest, in combination with microbiological proof of
registry, number NCT01831115) was a prospective, infection, or more than one of the major criteria. In cases
multicenter, diagnostic study enrolling adult patients of equivocal chest imaging (interstitial pattern, effu-
presenting with acute dyspnea to the emergency depart- sions), at least 2 major criteria were considered as
ment (ED) of 2 university hospitals (Basel and Zurich, necessary.
Switzerland). To enroll as many pneumonia patients as All patient records and discharge papers of patients
possible, acute dyspnea was the only criterion to be met, with an adjudicated final diagnosis of pneumonia were
with no other additional symptom suggestive of pneu- reviewed to classify them into CAP, hospital-acquired pneu-
monia. Patients were included irrespective of renal func- monia (HAP), or healthcare-associated pneumonia
tion, except for patients with terminal kidney failure on (HCAP) according to current practice guidelines (16, 17 ).
chronic hemodialysis who were excluded. For this analy-
sis, patients were not eligible if they had unavailable Pneumonia with proven specific bacterial pathogen. In pa-
measurements of one or more investigated inflammatory tients with an adjudicated final diagnosis of pneumonia,
biomarkers (procalcitonin, interleukin 6, CRP) at time of all available microbiological specimens and tests re-
presentation. quested by the treating physician were centrally re-
The study was carried out according to the princi- viewed by an experienced internist. Results were inter-
ples of the Declaration of Helsinki and was approved by preted in conjunction with consequential changes in
the local ethics committees. Written informed consent antimicrobial therapy and the patient’s clinical status.
was obtained from all patients. The authors designed the Therefore, in accordance with previous studies (18 ),
study, gathered and analyzed the data according to the bacterial pneumonia was considered to be absent if one
Standards for Reporting of Diagnostic Accuracy Group of the following conditions were met: an alternative
Table 1. Baseline characteristics in the diagnostic study according to the presence or absence of pneumonia.a
Demographics
Age, years 74.0 (62.0–82.0) 74.0 (62.0–82.0) 74.5 (61.0–81.0) 0.987
Female sex 310 (44.9%) 239 (46.7%) 71 (39.9%) 0.137
BMI,c kg/m2 25.7 (22.0–30.1) 25.8 (22.2–30.1) 24.9 (21.3–29.3) 0.183
Recent history
Cough 482 (71.8%) 329 (66.5%) 153 (86.9%) <0.001
Sputum production 346 (51.6%) 226 (45.7%) 120 (68.6%) <0.001
Weight gain 138 (21.6%) 108 (23.1%) 30 (17.5%) 0.158
Clinical parameters at ED
Systolic BP, mmHg 139.3 (±26.3) 141.6 (±26.9) 132.9 (±23.5) <0.001
Diastolic BP, mmHg 80.7 (±18.0) 82.9 (±17.9) 74.43 (±16.6) <0.001
Heart rate, bpm 94.0 (79.0–110.0) 92.0 (77.0–109.0) 97.0 (84.0–113.0) 0.011
Temperature, °C 37.4 (36.9–38.0) 37.3 (36.8–37.8) 37.9 (37.3–39.0) <0.001
Pulse oximetry, % 95.0 (92.0–98.0) 96.0 (93.0–98.0) 94.0 (90.0–96.0) <0.001
Respiratory rate, breaths/min 24.0 (18.0–28.0) 24.0 (18.0–28.0) 24.0 (18.0–32.0) 0.023
Rales 336 (50.1%) 220 (44.2%) 116 (67.1%) <0.001
Increased JVP 132 (20.7%) 111 (23.4%) 21 (12.7%) 0.004
Edema 271 (40.0%) 220 (43.7%) 51 (29.3%) 0.001
History variables
CRI 173 (25.1%) 128 (25.1%) 45 (25.3%) 1
CAD 225 (32.7%) 164 (32.1%) 61 (34.3%) 0.643
PAD 100 (14.9%) 74 (14.9%) 26 (15.1%) 1
COPD 299 (43.4%) 215 (42.1%) 84 (47.2%) 0.254
DM 163 (23.7%) 121 (23.7%) 42 (23.6%) 1
Dyslipidemia 268 (39.3%) 199 (39.3%) 69 (39.2%) 1
Hypertension 478 (69.6%) 359 (70.5%) 119 (66.9%) 0.394
MI 120 (17.5%) 88 (17.2%) 32 (18.2%) 0.818
Pneumonia 175 (25.7%) 109 (21.5%) 66 (37.5%) <0.001
Smoker (current or 484 (72.8%) 350 (71.3%) 134 (77.0%) 0.165
ex-smoker)
Immunsuppressiond 100 (14.5%) 72 (14.1%) 28 (15.7%) 0.621
Outpatient medication
Aspirin 241 (35.1%) 170 (33.4%) 71 (39.9%) 0.122
ACE inhibitors 220 (32.0%) 173 (34.0%) 47 (26.4%) 0.063
Aldosterone inhibitors 55 (8.0%) 45 (8.9%) 10 (5.6%) 0.201
ARB 114 (16.7%) 78 (15.4%) 36 (20.3%) 0.159
Beta blockers 270 (39.5%) 210 (41.5%) 60 (33.7%) 0.075
Calcium channel blockers 142 (20.7%) 96 (18.9%) 46 (25.8%) 0.054
Diuretics 349 (50.9%) 259 (51.1%) 90 (50.6%) 0.931
Antibiotics 71 (10.3%) 40 (7.9%) 31 (17.4%) 0.001
Laboratory parameters
Hemoglobin, g/L 135.0 (122.0–148.0) 136.0 (122.0–150.0) 131.0 (119.0–142.0) 0.001
WBC, ×103/μL 10.2 (7.6–13.6) 9.4 (7.2–12.2) 12.6 (8.7–16.8) <0.001
Continued on page 1536
Investigational parameters
CRP, mg/L 23.3 (5.9–69.2) 13.2 (4.2–46.2) 96.6 (40.5–189.4) <0.001
Interleukin 6, ng/L 15.5 (6.0–47.9) 10.6 (4.4–25.0) 54.7 (22.7–211.3) <0.001
Procalcitonin, ng/mL 0.09 (0.05–0.19) 0.07 (0.05–0.14) 0.19 (0.09–0.63) <0.001
a
Continuous variables are presented as means with SD; for nonnormal distribution, as medians with interquartile ranges. For comparison, t test or Mann–Whitney U-test were used
as appropriate. Categorical variables are shown as numbers and percentages. For comparison, Fisher’s exact test was used.
b
P value for comparison between non-pneumonia and pneumonia patients.
c
BMI, body mass index; BP, blood pressure; JVP, jugular venous pressure; CRI, chronic renal insufficiency; CAD, coronary artery disease; PAD, peripheral artery disease; COPD, chronic
obstructive pulmonary disease; DM, diabetes mellitus; MI, myocardial infarction; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; WBC, white blood cells
count.
d
Immunsuppression was defined as history of active cancer and/or chronic medication with ≥5 mg of oral prednisone or a dose equivalent.
(26 ). The sensitivity and negative predictive value of cur- formed in the randomized management study are de-
rently recommended rule-out cutoffs for inflammatory scribed in the Methods section in the online Data
conditions were calculated (27, 28 ). The percentage of Supplement.
patients eligible for rule out of pneumonia was used to
quantify effectiveness. The effectiveness does not deter- Results
mine how many patients are correctly ruled out, it only
shows the number of patients triaged toward rule out DIAGNOSTIC STUDY
(given that the plasma concentration of the investiga-
tional parameters was below the cutoff) when presenting Patients: demographics and characteristics. Overall, 690
to the ED irrespective of whether they have the final patients had the 3 inflammatory biomarkers measured
diagnosis of pneumonia or not. and hence were eligible for the diagnostic analysis (see
For nonnormally distributed data, correlations were Fig. 1 in the online Data Supplement). These patients
assessed by Spearman’s rank (rs) correlation coeffi- more often had symptoms and signs of pneumonia as
cient. In the diagnostic study, 6 subgroup analyses compared to patients without these measurements (see Ta-
were predefined: in patients with only internal (that is, ble 2 in the online Data Supplement). Median age was 74
available for the adjudicating physician) measure- years and 44.9% were women. AHF was the adjudicated
ments (1 ) or only external (that is, unavailable for the final diagnosis in 311 patients (45.1%) and pneumonia in
adjudicating physician) measurements (2 ) of procalci- 178 patients (25.8%), with 58 patients (8.4%) adjudicated
tonin to address the potential effect of inclusion bias; in to have both AHF and concurrent pneumonia. Of 178 pa-
patients with pneumonia and proven specific bacterial tients with an adjudicated final diagnosis of pneumonia,
pathogen (3 ); and in patients with final diagnosis of pneu- 150 (84.3%), 26 (14.6%), and 2 (1.1%) presented with
monia with (4 ) or without (5 ) concurrent AHF. Further- CAP, HCAP, and HAP, respectively.
more, a sensitivity analysis including patients with at least 1
additional symptom suggestive of pneumonia (temperature Inflammatory biomarkers. In our diagnostic study, CRP
ⱖ38.0 °C, cough, sputum production, or lung infiltrate) measurements were available for the adjudicating physi-
was performed (6 ). cian in all patients (100%), procalcitonin measurements
The interaction P values between the biomarker’s in 453 patients (65.5%), and interleukin 6 measurements
AUC in the overall cohort and the biomarker’s AUC in a in no patient (0%). Procalcitonin, interleukin 6, and
specific subgroup were calculated with a logistic regres- CRP were significantly higher in patients with pneumo-
sion model for the prediction of pneumonia. nia than in those without (Table 1). CRP and interleukin
Statistical analyses were performed with SPSS for 6 (rs ⫽ 0.69; P ⬍ 0.001) as well as CRP and procalci-
Windows 25.0 (SPSS Inc.), R statistical Software Ver- tonin (rs ⫽ 0.61; P ⬍ 0.001) plasma concentrations were
sion 3.4.3 (MathSoft), and MedCalc Version 17.9.7 moderately correlated. Procalcitonin and interleukin 6
(MedCalc, Software). All hypothesis testing was plasma concentrations also showed a moderate correla-
2-tailed, and P values of ⬍0.05 were considered to tion (rs ⫽ 0.54; P ⬍ 0.001). When compared to procal-
indicate statistical significance. Statistical analyses per- citonin (AUC ⫽ 0.75; 95% CI, 0.71– 0.78), interleukin
Effectivenessa (Percentage
Biomarker Plasma concentration Sensitivity Negative predictive value fulfilling criteria, n)
systemic concentrations of procalcitonin and CRP, this is calculation was performed for this secondary analysis
an essential difference, particularly in patients presenting of BASEL V. Although this is one of the largest diag-
early after symptom onset (6, 17 ). In full agreement with nostic studies with central adjudication by 2 indepen-
this concept, the results of this study document that es- dent experts performed until now, it might have been
tablished low cutoffs for both procalcitonin and CRP do underpowered for some comparisons. Second, al-
not have sufficiently high negative predictive value to though we used one of the most stringent methods to
reliably exclude CAP in general and pneumonia with adjudicate for the presence or absence of pneumonia
proven specific bacterial pathogen in particular. including central adjudication, we may still have mis-
For the second possible clinical consequence, short- classified a small number of patients. However, this
ening the duration of antibiotic therapy, it is important misclassification would have resulted in an underesti-
to highlight that some, but not all, open-label random- mation of the true AUCs of all biomarkers examined
ized controlled trials evaluating procalcitonin guidance and could not explain the significantly higher AUC
in combination with the standard of care (always includ- observed for blinded interleukin 6 as compared to pro-
ing CRP) vs the local standard of care were able to show calcitonin mostly available to the adjudicating physi-
a reduction in days on antibiotics (9 –11, 34, 35 ). In cian. Third, we cannot generalize our findings to pa-
general, procalcitonin guidance was able to reduce the tients with terminal kidney failure requiring dialysis
number of days when the standard of care tended to because these patients were excluded. Fourth, the ran-
include rather long durations of treatment with poor domized management study was stopped prematurely
stewardship, but not when compared against a contem- and therefore has limited statistical power.
porary standard of care with strict stewardship. In conclusion, in patients presenting with dyspnea,
Several limitations merit consideration when in- diagnostic accuracy of procalcitonin for pneumonia is
terpreting our findings: first, no specific sample size only moderate and lower than that of interleukin 6 or
Table 3. Primary and secondary endpoints in the overall study population and in patients randomized to intervention in the
randomized management study.a
Duration of antibiotic treatment, days 10.5 (6.8–13.0) 10.5 (6.0–12.2) 10.5 (8.8–13.2) 0.387
Duration of hospital stay, days 11.5 (6.0–22.5) 10.0 (6.0–18.2) 14.0 (6.8–24.2) 0.388
Inhospital mortality, n (%) 9 (20.5) 5 (20.8) 4 (20.0) 1.000
Duration of antibiotic treatment, days 10.5 (6.0–12.2) 12.0 (11.0–14.5) 6.0 (6.0–6.0) <0.001
Duration of hospital stay, days 10.0 (6.0–18.2) 16.0 (8.5–27.0) 6.0 (5.0–6.0) 0.004
Inhospital mortality, n (%) 5 (20.8) 4 (26.7) 1 (11.1) 0.697
a
Continuous variables are presented as medians with interquartile ranges and categorical variables as numbers and percentages. For comparisons, Mann–Whitney U or chi-square
tests were used as appropriate.
b
P value for comparison between intervention and control group.
c
P value for comparison between antibiotic therapy sustained and stopped group.
CRP. Overall, the clinical utility of procalcitonin was Cardiovascular Research Foundation Basel, the University of Basel,
lower than expected. the University Hospital Basel, Critical Diagnostics, Abbott, Alere,
BRAHMS, Roche, and Singulex. J. Boeddinghaus, the University Hospital
Basel (Division of Internal Medicine), the Gottfried and Julia Bangerter-
Rhyner Foundation, the Swiss Academy of Medical Sciences; R. Tweren-
Author Contributions: All authors confirmed they have contributed to bold, the Swiss National Science Foundation (Grant No P300PB-167803/
the intellectual content of this paper and have met the following 4 require- 1), the Swiss Heart Foundation, the Cardiovascular Research Foundation
ments: (a) significant contributions to the conception and design, acquisi- Basel, the University of Basel and the University Hospital Basel; K. Wildi,
tion of data, or analysis and interpretation of data; (b) drafting or revising the FAG Basel and the Julia und Gottfried Bangerter-Rhyner Stiftung; T.
the article for intellectual content; (c) final approval of the published article; Breidthardt, research grants from the Swiss National Science Foundation
and (d) agreement to be accountable for all aspects of the article thus (PASMP3-134362), the University Hospital Basel, the Department of In-
ensuring that questions related to the accuracy or integrity of any part of the ternal Medicine, University Hospital Basel, Abbott, and Roche; C. Muel-
article are appropriately investigated and resolved. ler, research grants from the Swiss National Science Foundation, the Swiss
Heart Foundation, the European Union, the Cardiovascular Research
D. Wussler, statistical analysis, administrative support, provision of Foundation Basel, the KTI, the University of Basel, Abbott, Alere, Astra
study material or patients; N. Kozhuharov, statistical analysis; M.T. Zeneca, Beckman Coulter, BG medicine, Biomerieux, BRAHMS, Critical
Oliveira, provision of study material or patients; A. Bossa, administra- Diagnostics, Roche, Siemens, Singulex, Sphingotec; C. Puelacher, research
tive support, provision of study material or patients; J. du Fay de La- support from the University Hospital Basel and the PhD Education Plat-
vallaz, statistical analysis, administrative support; R. Twerenbold, fi- form for Health Sciences outside the submitted work.
nancial support, statistical analysis, administrative support, provision of Expert Testimony: None declared.
study material or patients; D. Flores, administrative support, provision Patents: None declared.
of study material or patients; T. Nestelberger, provision of study mate-
rial or patients; J. Walter, statistical analysis; L. Koechlin, administra- Role of Sponsor: The funding organizations played no role in the
tive support; A. von Eckardstein, provision of study material or pa- design of study, choice of enrolled patients, review and interpretation of
tients; T. Breidthardt, statistical analysis, administrative support; C. data, preparation of manuscript, or final approval of manuscript.
Mueller, financial support, statistical analysis, administrative support, Acknowledgments: The authors thank the patients who participated
provision of study material or patients. in the study, the staff of the participating emergency departments, the
D. Wussler, N. Kozhuharov, Z. Sabti, and C. Mueller had full access to research coordinators, and the laboratory technicians (particularly Mi-
all the data in the study and take the responsibility for the integrity of chael Freese, Caroline Kulangara, Claudia Stelzig, Kathrin Meissner,
the data and the accuracy of the data analysis. Christine Kruse, Irina Klimmeck, Janine Voegele, Beate Hartmann,
Ina Ferel, Natascha Herr, and Fausta Chiaverio) for their most valuable
Authors’ Disclosures or Potential Conflicts of Interest: Upon man- efforts.
uscript submission, all authors completed the author disclosure form. Dis-
closures and/or potential conflicts of interest:
Additional contributors to this article:
Employment or Leadership: None declared.
Consultant or Advisory Role: J. Boeddinghaus, Siemens; R. Tweren- Alexandre Soeiro,12 Priscila Goldstein,12 Tânia Stra-
bold, Roche Diagnostics, Abbott Diagnostics, Siemens, Singulex,
belli,12 Célia Strunz,12 Karin Wildi,13,14 Christian Pu-
BRAHMS; C. Mueller, Abbott, Alere, Astra Zeneca, Biomerieux,
BMS, Boehringer Ingelheim, BRAHMS, Cardiorentis, Eli Lilly, No- elacher,13,15 Katharina Rentsch,16 and Assen Goudev.17
vartis, Roche, Sanofi, Siemens, and Singulex.
Stock Ownership: None declared.
Honoraria: J. Boeddinghaus, Siemens; R. Twerenbold, Roche Diag-
nostics, Abbott Diagnostics, Siemens, Singulex, BRAHMS; T. 12
Breidthardt, Roche; C. Mueller, Abbott, Alere, Astra Zeneca, Emergency Department, INCOR, Sao Paulo, Brazil; 13 Cardiovascular Research Institute
Basel (CRIB) and Department of Cardiology, University Hospital Basel, University of Basel,
Biomerieux, BMS, Boehringer Ingelheim, BRAHMS, Cardiorentis, Eli
Switzerland; 14 Critical Care Research Group, The Prince Charles Hospital and University of
Lilly, Novartis, Roche, Sanofi, Siemens, and Singulex; A. Goudev, Queensland, Brisbane, Australia; 15 Department of Internal Medicine, University Hospital
Pfizer, Novartis, AstraZeneca, and Amgen. Basel, University of Basel, Switzerland; 16 Department of Laboratory Medicine, University
Research Funding: Research grants from the European Union, the Hospital Basel, Switzerland; 17 Queen Ioanna University Hospital Sofia, Medical University
Swiss National Science Foundation, the Swiss Heart Foundation, the of Sofia, Bulgaria.
References
1. Ray P, Birolleau S, Lefort Y, Becquemin M-H, Beigelman JGF, Coats AJS, et al. 2016 ESC Guidelines for the diag- agement of community-acquired bacterial pneumonia:
C, Isnard R, et al. Acute respiratory failure in the elderly: nosis and treatment of acute and chronic heart failure. what is new since the 2007 Infectious Diseases Society
etiology, emergency diagnosis and prognosis. Crit Care Eur J Heart Fail 2016;18:891–975. of America/American Thoracic Society guidelines. Am J
2006;10:R82. 5. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Emerg Med 2013;31:602–12.
2. Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Drazner MH, et al. 2013 ACCF/AHA guideline for the 8. Maisel A, Neath S-X, Landsberg J, Mueller C, Nowak RM,
Manning HL, Bourbeau J, et al. An official American Tho- management of heart failure: executive summary: a re- Peacock WF, et al. Use of procalcitonin for the diagno-
racic Society statement: update on the mechanisms, as- port of the American College of Cardiology Foundation/ sis of pneumonia in patients presenting with a chief
sessment, and management of dyspnea. Am J Respir American Heart Association Task Force on Practice complaint of dyspnoea: results from the BACH (Bio-
Crit Care Med 2012;185:435–52. Guidelines. Circulation 2013;128:1810 –52. markers in Acute Heart Failure) trial. Eur J Heart Fail
3. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schin- 6. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, 2012;14:278 – 86.
dler C, Buser P, et al. Use of B-type natriuretic peptide in Le Jeune I, et al. BTS guidelines for the management of 9. Christ-Crain M, Stolz D, Bingisser R, Mueller C, Leuppi J,
the evaluation and management of acute dyspnea. community acquired pneumonia in adults: update Battegay M, et al. Procalcitonin guidance significantly
N Engl J Med 2004;350:647–54. 2009. Thorax 2009;Suppl 3:iii1–55. reduces antibiotic duration in community-acquired
4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland 7. Moran GJ, Rothman RE, Volturo GA. Emergency man- pneumonia: the “ProCAP” study. Crit Care 2005;9:166.